TISIDB

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF02984 Cyclin PF00134 Cyclin
Function	Essential for the control of the cell cycle at the G1/S (start) transition.

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0006260 DNA replication GO:0006261 DNA-dependent DNA replication GO:0006270 DNA replication initiation GO:0009755 hormone-mediated signaling pathway GO:0016055 Wnt signaling pathway GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030521 androgen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0043401 steroid hormone mediated signaling pathway GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0048545 response to steroid hormone GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0198738 cell-cell signaling by wnt
Molecular Function	GO:0003713 transcription coactivator activity GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity GO:0019207 kinase regulator activity GO:0019887 protein kinase regulator activity GO:0035257 nuclear hormone receptor binding GO:0035258 steroid hormone receptor binding GO:0050681 androgen receptor binding GO:0051427 hormone receptor binding
Cellular Component	GO:0000307 cyclin-dependent protein kinase holoenzyme complex GO:0061695 transferase complex, transferring phosphorus-containing groups GO:1902554 serine/threonine protein kinase complex GO:1902911 protein kinase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle hsa04114 Oocyte meiosis hsa04115 p53 signaling pathway hsa04151 PI3K-Akt signaling pathway
Reactome	R-HSA-390471: Association of TriC/CCT with target proteins during biosynthesis R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-69278: Cell Cycle, Mitotic R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-390466: Chaperonin-mediated protein folding R-HSA-69656: Cyclin A R-HSA-69202: Cyclin E associated events during G1/S transition R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence R-HSA-113510: E2F mediated regulation of DNA replication R-HSA-1538133: G0 and Early G1 R-HSA-69615: G1/S DNA Damage Checkpoints R-HSA-69206: G1/S Transition R-HSA-69205: G1/S-Specific Transcription R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-392499: Metabolism of proteins R-HSA-453279: Mitotic G1-G1/S phases R-HSA-8849470: PTK6 Regulates Cell Cycle R-HSA-69200: Phosphorylation of proteins involved in G1/S transition by active Cyclin E R-HSA-391251: Protein folding R-HSA-69242: S Phase R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21 R-HSA-162582: Signal Transduction R-HSA-8848021: Signaling by PTK6 R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-69563: p53-Dependent G1 DNA Damage Response R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle
hsa04114 Oocyte meiosis
hsa04115 p53 signaling pathway
hsa04151 PI3K-Akt signaling pathway

Reactome

R-HSA-390471: Association of TriC/CCT with target proteins during biosynthesis
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-390466: Chaperonin-mediated protein folding
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-113510: E2F mediated regulation of DNA replication
R-HSA-1538133: G0 and Early G1
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-69206: G1/S Transition
R-HSA-69205: G1/S-Specific Transcription
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-392499: Metabolism of proteins
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-8849470: PTK6 Regulates Cell Cycle
R-HSA-69200: Phosphorylation of proteins involved in G1/S transition by active Cyclin E
R-HSA-391251: Protein folding
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-162582: Signal Transduction
R-HSA-8848021: Signaling by PTK6
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCNE1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCNE1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCNE1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.298	0.303
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.438	0.711
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.202	0.837
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.817	0.161
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.833	0.45
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.814	0.616
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.249	0.441
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.63	0.521
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.299	0.748
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.292	0.7
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.622	0.503
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.598	0.000436

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCNE1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCNE1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCNE1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCNE1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCNE1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCNE1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCNE1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCNE1
Name	cyclin E1
Aliases	cyclin Es; cyclin Et; CCNE; pCCNE1; cyclin E variant ex5del; cyclin E variant ex7del; pluripotent specific c ......
Chromosomal Location	19q12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCNE1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CCNE1